COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Subscribe To Our Newsletter & Stay Updated
